A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC

Part of paid clinical trials in Los Angeles, California.

Sponsor
Amgen
Study ID
NCT06745323
Phase
PHASE2
Status
Active Not Recruiting

Conditions

  • Small Cell Lung Cancer (SCLC)

Eligibility Criteria

Sex
ALL
Age
18 Years - 99 Years
Healthy Volunteers
Not accepted

Interventions

  • Tarlatamab — DRUG
    Tarlatamab will be administered by IV infusion.

Study Details

The primary objective of this study is to describe the antitumor activity of tarlatamab in participants with small cell lung cancer (SCLC).

Key Dates

Start date
Feb 26, 2025
Status verified
Feb 2026
Primary completion
Feb 9, 2029
Completion
Feb 9, 2029

Study Design

Enrollment
252 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment Arm A: Dose 1 Tarlatamab
    Participants will receive dose 1 of Tarlatamab by intravenous (IV) infusion during the treatment period.
  • Experimental: Treatment Arm B: Dose 2 Tarlatamab
    Participants will receive dose 2 of Tarlatamab by IV infusion during the treatment period.
  • Experimental: Treatment Arm C: Dose 3 Tarlatamab
    Participants will receive dose 3 of Tarlatamab by IV infusion during the treatment period.

Primary Outcome Measure

Proportion of participants with confirmed objective response to Tarlatamab [ Time Frame: Approximately 52 Months ]

Locations (12)

FacilityCityStateZIPSite coordinators
University of California Los AngelesLos AngelesCalifornia90095-
Hartford HealthCare Cancer Institute at The Hospital of Central ConnecticutPlainvilleConnecticut06062-
AdventHealth Hematology and OncologyOrlandoFlorida32804-
City of Hope ChicagoRockfordIllinois61108-
Health Partners Cancer Center at Regions HospitalSaint PaulMinnesota55101-
New York Oncology Hematology PCAlbanyNew York12206-
Duke UniversityDurhamNorth Carolina27705-
FirstHealth Cancer CenterPinehurstNorth Carolina28374-
Guthrie Medical GroupSayrePennsylvania18840-
Tennessee Oncology PLLC - ChattanoogaChattanoogaTennessee37404-
Tennessee Oncology, PLLCNashvilleTennessee37203-
Virginia Cancer Specialists PCFairfaxVirginia22031-

Find similar trials in Los Angeles, CA

By research site
University of California Los Angeles· Los Angeles, CAHartford HealthCare Cancer Institute at The Hospital of Central Connecticut· Plainville, CTAdventHealth Hematology and Oncology· Orlando, FLCity of Hope Chicago· Rockford, ILHealth Partners Cancer Center at Regions Hospital· Saint Paul, MNNew York Oncology Hematology PC· Albany, NY

Related Studies